deutsche gesellschaft für humangenetik e.v.

gfh

Indication Criteria for Genetic Testing
Evaluation of validity and clinical utility

Indication criteria for disease:
Huntington disease, Chorea Huntington [HD]

Ad hoc Committee „Indication Criteria for Genetic Testing"
Ad hoc-Kommission „Indikationskriterien für genetische Diagnostik"

Chairman of the Committee

Prof. Dr. med. Jörg Schmidtke,
Institute of Human Genetics
Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover
Tel. 0049 (0)511-532 6538
Fax 0049 (0)511 532 5865
schmidtke.joerg@mh-hannover.de

Members of the Committee

Prof. Dr. med. Gabriele Gillessen-Kaesbach
Prof. Dr. med. Tiemo Grimm
Prof. Dr. med. André Reis
Prof. Dr. med. Eberhard Schwinger
Prof. Dr. med. Peter Wieacker
Prof. Dr. med. Klaus Zerres
Prof. Dr. med. Johannes Zschocke

1. General information on authorship

Name and address of institution:
Name: *Institute of Human Genetics, Medical University Lübeck*
Address: *Ratzeburger Allee 160*
Postcode: *D-23538*
City: *Lübeck*
Tel.:   *+49-451-500-2620*
Fax: *+49-451-500-4187*
E-mail: *marianne.schirr@uk-sh.de*
Internet: *http://www.humangenetik.mu-luebeck.de*

Head of the institution:
Name: *Prof. Dr. Gabriele Gillesen-Kaesbach*
Tel.:   *+49-451-500-2620*
Fax: *+49-451-500-4187*
E-mail: *g.gillesen@uk-sh.de*

Author of this text, date:
Name: *Prof. Dr. med. Eberhard Schwinger*
Tel.:   *+49-451-500-6055*
Fax: *+49-451-500-4187*
E-mail: *schwing@uni-luebeck.de*
Date: *13.06.2007*

Reviewer, validation date:
Name: *Prof. Dr.med. Barbara Zoll*
Tel.:   *+49-551-39-7591*
Fax: *+49-551-39-7567*
E-mail: *bzoll1@gwdg.de*
Date: *09.08.2007*

Translator, translation date:
Name: *Prof. Dr. Ulrich Langenbeck*
E-mail.:   *Ulrich.Langenbeck@gmx.net*
Date: *10.03.2008*

Re-editor, date:
Name:
Tel.:
Fax:
E-mail:
Date:

Authorized by gfh Ad hoc Committee „Indication Criteria for Genetic Testing"

Date: 20.05.2008

Updated by

Date:

2. Disease characteristics

2.1 Name of the Disease (Synonyms):
Huntington disease, Chorea Huntington, HD

2.2 OMIM# of the Disease: *143100*

2.3 Name of the Analysed Genes or DNA/Chromosome Segments: *HD*

2.4 OMIM# of the Gene(s): *143100*

2.5 Mutational Spectrum:
CAG repeat expansion

2.6 Analytical Methods:
PCR. In not unambiguous cases the analysis of HD-like genes HDL1 and 2 may be considered.

2.7 Analytical Validation
Parallel analysis of negative and positive controls.

2.8 Estimated Frequency of the Disease in Germany
(Incidence at birth ("birth prevalence") or population prevalence):
Prevalence at birth. 1:10,000

2.9 If applicable, prevalence in the ethnic group of investigated person:
*not applicable*

2.10 Diagnostic Setting:

	Yes.	No.
A. (Differential)diagnostics	☒	☐
B. Predictive Testing	☒	☐
C. Risk assessment in Relatives	☒	☐
D. Prenatal	☒	☐

Comment:

---

3. Test characteristics

test		genotype or disease	
		present	absent
	pos.	A	B
	neg.	C	D

A: true positives   C: false negatives
B: false positives   D: true negatives

sensitivity: A/(A+C)
specificity: D/(D+B)
pos. predict. value: A/(A+B)
neg. predict. value: D/(C+D)

3.1 Analytical Sensitivity
(proportion of positive tests if the genotype is present)
nearly 100%

3.2 Analytical Specificity
(proportion of negative tests if the genotype is not present)
nearly 100%

3.3 Clinical Sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Nearly 100% if family history is informative and symptoms are typical of HD.

3.4 Clinical Specificity
(proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Depends on age and family history of test person;
with conspicuous family history and age < 40 years almost 50%, at higher age > 50%.

3.5 Positive clinical predictive value
(life time risk to develop the disease if the test is positive).
Nearly 100% at allele size of > 40 CAG repeats.

3.6 Negative clinical predictive value
(Probability not to develop the disease if the test is negative).
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.

Index case in that family had been tested:
Nearly 100%

Index case in that family had not been tested:
Can only be resolved by testing the non-affected individual.

_____

4. Clinical Utility

4.1 (Differential)diagnosis: The tested person ist clinically affected
(To be answered if in 2.10 "A" was marked)

4.1.1 Can a diagnosis be made other than through a genetic test?

No.   ☒ (continue with 4.1.4)
Yes,   ☐
     clinically.   ☐
     imaging.   ☐
     endoscopy.   ☐
     biochemistry.   ☐
     electrophysiology.   ☐
     other (please describe)

4.1.2 Describe the burden of alternative diagnostic methods to the patient

4.1.3 How ist the cost effectiveness of alternative diagnostic methods to be judged?

4.1.4 Will disease management be influenced by the result of a genetic test?

No.   ☒

Yes.   ☐
     Therapy (please describe)
     Prognosis (please describe)
     Management (please describe)

_____

4.2 Predictive Setting: The tested person is clinically unaffected but carries an increased risk based on family history
   (To be answered if in 2.10 "B" was marked)

4.2.1 Will the result of a genetic test influence lifestyle and prevention?
Yes.

If the test result is positive (please describe)
e.g. choice of occupation, family planning

If the test result is negative (please describe)
e.g. choice of occupation, family planning

4.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?
e.g. choice of occupation, family planning

4.3 Genetic risk assessment in family members of a diseased person
   (To be answered if in 2.10 "C" was marked)

4.3.1 Does the result of a genetic test resolve the genetic situation in that family?
Yes.

4.3.2 Can a genetic test in the index patient save genetic or other tests in family members?
Yes.

4.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member?
Yes.

4.4 Prenatal diagnosis
   (To be answered if in 2.10 "D" was marked)

4.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic?
Yes.

5. If applicable, further consequences of testing
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
Knowledge of the genetic situation can be important for the tested persons for planning their future life, and it can be either a strain or a relief.